BRAF V600E mutation positive

3 trials 2 recruiting MedDRA PT
3 Registered trials
2 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
V Various (ATC V) 1
L Oncology (ATC L) 1
— ATC code not specified 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 1 substance
RAF/BRAF inhibitor 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Iovance Biotherapeutics Inc. Commercial
    (3R)-N-[3-[5-(2-CYCLOPROPYLPYRIMIDIN-5-YL)-1H-PYRROLO[2,3-B]PYRIDINE-3-CARBONYL]-2,4-DIFLUOROPHENYL]-3-FLUOROPYRROLIDINE-1-SULFONAMIDE; COBICISTAT
    2024-513578-23-00 7 countries 2023 n=134
    Recruiting
  • Intergroupe Francophone De Cancerologie Thoracique Academic
    BINIMETINIB; ENCORAFENIB
    2024-515944-22-00 1 country 2021 n=119
    Ended
  • Vall D Hebron Institute Of Oncology Academic
    IMP not specified
    2023-509564-22-00 1 country 2025 n=25
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Iovance Biotherapeutics Inc. Commercial 1 Phase II 1
Intergroupe Francophone De Cancerologie Thoracique Academic 1 Phase II 0
Vall D Hebron Institute Of Oncology Academic 1 Phase II 1
New trials by year
2021
1
2023
1
2025
1
← All indication landscapes